Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Carlisle

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Methods in Enzymology|January 1, 1979
Neuronal cells from rodent neoplasmsD Schubert, W Carlisle
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 6, 2025
Setting Expectations: Using Real-World Data to Guide Patients on Frontline OsimertinibJennifer W Carlisle, Ticiana Leal
Cancer|August 21, 2023
Advancing immunotherapy in small cell lung cancerJennifer W Carlisle, Ticiana Leal
Nature Reviews. Clinical Oncology|December 13, 2018
A banner year for immunotherapy and targeted therapyJennifer W Carlisle, Suresh S Ramalingam
Translational Lung Cancer Research|February 11, 2020
Improving outcomes for brain metastases in EGFR mutated NSCLCJennifer W Carlisle, Suresh S Ramalingam
Future Oncology (London, England)|January 19, 2019
Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancerJennifer W Carlisle, Suresh S Ramalingam
Cancer|January 1, 1970
Adenocarcinoma of the prostate simulating primary rectal malignancyB S Olsen, R W Carlisle
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2021
Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, and Proteolysis-Targeting Chimeras: The Pharmacology of Cutting-Edge Lung Cancer TherapiesJennifer W Carlisle, R Donald Harvey
Future Oncology (London, England)|September 3, 2024
Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS studySuresh S Ramalingam, Jennifer W Carlisle
Nature|March 27, 1975
Putative neurotransmitters in clonal cell linesD Schubert, W Carlisle, C Look
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Methods in Enzymology|January 1, 1979
Neuronal cells from rodent neoplasmsD Schubert, W Carlisle
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 6, 2025
Setting Expectations: Using Real-World Data to Guide Patients on Frontline OsimertinibJennifer W Carlisle, Ticiana Leal
Cancer|August 21, 2023
Advancing immunotherapy in small cell lung cancerJennifer W Carlisle, Ticiana Leal
Nature Reviews. Clinical Oncology|December 13, 2018
A banner year for immunotherapy and targeted therapyJennifer W Carlisle, Suresh S Ramalingam
Translational Lung Cancer Research|February 11, 2020
Improving outcomes for brain metastases in EGFR mutated NSCLCJennifer W Carlisle, Suresh S Ramalingam
Future Oncology (London, England)|January 19, 2019
Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancerJennifer W Carlisle, Suresh S Ramalingam
Cancer|January 1, 1970
Adenocarcinoma of the prostate simulating primary rectal malignancyB S Olsen, R W Carlisle
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2021
Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, and Proteolysis-Targeting Chimeras: The Pharmacology of Cutting-Edge Lung Cancer TherapiesJennifer W Carlisle, R Donald Harvey
Future Oncology (London, England)|September 3, 2024
Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS studySuresh S Ramalingam, Jennifer W Carlisle
Nature|March 27, 1975
Putative neurotransmitters in clonal cell linesD Schubert, W Carlisle, C Look
Pageof 5